Ziritaxestat; 1628260-79-6; GLPG-1690; GLPG1690; 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile; GLPG-1690(Ziritaxestat); Ziritaxestat [USAN]; CHEMBL3828074; G451990; I02418V13W; G-451990; 2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]-methylamino]-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile; 5-Thiazolecarbonitrile, 2-((2-ethyl-6-(4-(2-(3-hydroxy-1-azetidinyl)-2-oxoethyl)-1-piperazinyl)-8-methylimidazo(1,2-a)pyridin-3-yl)methylamino)-4-(4-fluorophenyl)-; Ziritaxestatn; 2-[[2-Ethyl-8-Methyl-6-[4-[2-(3-Oxidanylazetidin-1-Yl)-2-Oxidanylidene-Ethyl]piperazin-1-Yl]imidazo[1,2-A]pyridin-3-Yl]-Methyl-Amino]-4-(4-Fluorophenyl)-1,3-Thiazole-5-Carbonitrile; Ziritaxestat (USAN/INN); ZIRITAXESTAT [INN]; Ziritaxestat (GLPG1690); GTPL9561; SCHEMBL16051264; UNII-I02418V13W; BCP20895; EX-A1646; BDBM50187686; MFCD31544330; s8895; WHO 11017; CS-7634; DB15403; SB19736; compound 11 [PMID: 28414242]; AC-36149; HY-101772; J3.652.431F; D11844; A902613; Q23075652; 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;GLPG1690; 42-ETHYL-14-FLUORO-83-HYDROXY-3,48-DIMETHYL-7-OXO-3-AZA-4(3,6)-IMIDAZO(1,2-A)PYRIDINA-5(1,4)-PIPERAZINA-2(4,2)-(1,3)THIAZOLA-8(1)-AZETIDINA-1(1)-BENZENAOCTAPHANE-25-CARBONITRILE